

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Equality impact assessment – Scoping

#### Relugolix–estradiol–norethisterone acetate for treating symptoms of endometriosis [ID3982]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation it was highlighted that the technology should be available to all eligible people, which may include transgender men or non-binary people.

It was also noted that people from some minority ethnic groups may be underdiagnosed, and/or present later and thus with more severe symptoms and that they are more likely to receive lower quality care due to a higher likelihood of living in areas of high deprivation, having lower incomes, experiencing language barriers and having poorer access to women's healthcare services.

The NICE technical team also notes that:

- The use of treatments which are contraceptive may not be acceptable to people from some religious or ethnic groups
- Delaying childbearing, either by choice or because of subfertility, may be a risk factor for endometriosis.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider all people that are eligible for treatment when making recommendations and whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope have been made. The population in the draft scope and final scope refers to 'adults' and therefore includes all eligible people.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 26 July 2023